Analyst consensus rating
Denali Therapeutics Analyst Rating: Strong Buy
Direct answer
Denali Therapeutics's consensus rating is Strong Buy.
16 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $35.50.
Forecast evidence checked October 31, 2026.
Get free Denali Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $18.94
- Average price target
- $35.50
- High price target
- $42.00
- Low price target
- $23.00
- Low target gap
- +21.4%
- Target upside
- +87.4%
- High target gap
- +121.8%
- Target range width
- 100.3%
- Consensus rating
- Strong Buy
- Analysts
- 16
- Evidence date
- October 31, 2026
- Valid through
- November 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Denali Therapeutics?
Denali Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $35.50.
How far are Denali Therapeutics's low and high targets from the recorded price?
The low target implies +21.4%, while the high target implies +121.8%.
How many analysts are included in Denali Therapeutics's consensus?
The verified consensus includes 16 analysts.
How is Denali Therapeutics's target upside or downside calculated?
The average target of $35.50 is divided by the recorded price of $18.94, then one is subtracted to produce +87.4%. This does not guarantee a future return.
When was Denali Therapeutics's analyst forecast verified?
The data was verified on 2026-10-31. The dataset is valid through 2026-11-07.